Clinical Trial Update: Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating lorlatinib in ALK inhibitor-treated unresectable advanced or recurrent ALK-positive non-small cell lung cancer patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lorbrena (lorlatinib)

Snippet

Sponsor: Pfizer | Conditions: Advanced Non-Small Cell Lung Cancer | Phase 4 | Status: COMPLETED | Results posted: 2024-12-20